Edition:
United States

Merck Says Keytruda Showed Improved Overall Survival In Head & Neck Cancer Trial


Friday, 31 May 2019 06:45am EDT 

May 31 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DEMONSTRATES IMPROVED OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AT FINAL ANALYSIS OF PIVOTAL PHASE 3 KEYNOTE-048 TRIAL.MERCK & CO - FOR DUAL PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL, STATISTICAL SIGNIFICANCE NOT ACHIEVED FOR KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY IN CPS≥20 POPULATION VERSUS EXTREME REGIMEN.MERCK & CO - FOR CPS ≥1 POPULATION KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 35% IN THESE PATIENTS, WITH SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.MERCK & CO - KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 40% IN PATIENTS WHOSE TUMORS EXPRESSED PD-L1 WITH CPS≥20, SHOWING SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.